Manufacturing methods to control C-terminal lysine, galactose and sialic acid content in recombinant proteins

摘要

#$%^&*AU2020203864A120200702.pdf#####ABSTRACT OF THE DISCLOSURE Provided herein is a method for producing an antibody, such as an anti-TNFa antibody (e.g., infliximab) having a C-terminal lysine content of about 20% to about 70%, and a sialic acid content of about 1% to about 20%, comprising culturing a zinc-responsive host cell transfected with DNA encoding the antibody in a culture medium comprising at least 0.5 pM zinc; and controlling the concentration of zinc in the culture medium, thereby producing the antibody. 2